Does Rallies show Form 4 insider transactions for CVRX?

Yes. Rallies tracks CVRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CVRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CVRX. It does not provide personalized investment advice.

CVRX (CVRx, Inc. Common Stock) Stock Analysis - Insider Trades

CVRx, Inc. Common Stock (CVRX) is a publicly traded Healthcare sector company. As of May 21, 2026, CVRX trades at $6.06 with a market cap of $157.62M and a P/E ratio of -3.00. CVRX moved +1.08% today. Year to date, CVRX is -20.99%; over the trailing twelve months it is -13.30%. Its 52-week range spans $4.30 to $18.55. Analyst consensus is buy with an average price target of $10.50. Rallies surfaces CVRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CVRX stock inside the company?

Recent CVRX insider activity includes Adamson Philip B. sold 1.26K, Hykes Kevin sold 7.76K, VERRASTRO PAUL sold 1.28K, OASHEIM JARED sold 1.74K, and John Robert Allen sold 3.96K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CVRX Key Metrics

Key financial metrics for CVRX
Metric	Value
Price	$6.06
Market Cap	$157.62M
P/E Ratio	-3.00
EPS	$-2.01
Dividend Yield	0.00%
52-Week High	$18.55
52-Week Low	$4.30
Volume	0
Avg Volume	0
Revenue (TTM)	$59.07M
Net Income	$-52.66M
Gross Margin	86.18%

Recent CVRX Insider Trades

Adamson Philip B. sold 1.26K (~$9.97K) on Mar 2, 2026.
Hykes Kevin sold 7.76K (~$61.35K) on Mar 2, 2026.
VERRASTRO PAUL sold 1.28K (~$10.15K) on Mar 2, 2026.
OASHEIM JARED sold 1.74K (~$13.78K) on Mar 2, 2026.
John Robert Allen sold 3.96K (~$31.33K) on Mar 2, 2026.

Latest CVRX News

Humana Covers Barostim for 5.2M Medicare Advantage Members Starting May 2026 — May 14, 2026
CVRx Inc Q1 Revenue Climbs 20% to $14.8M; 257 U.S. Implant Centers — May 11, 2026
CVRx Nominates Former Axogen CEO Michael Dale to Board Before June 1 Annual Meeting — Apr 20, 2026
CVRx, Inc. Q1 Revenue Grows 20% to $14.8M, Gross Margin at 87% — Apr 13, 2026
CVRx Q4 Loss Widens to $0.46, Revenue Climbs 4.5% to $16.02M — Feb 12, 2026

CVRX Analyst Consensus

6 analysts cover CVRX: 0 strong buy, 5 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.50.

Common questions about CVRX

Who is trading CVRX stock inside the company?: Recent CVRX insider activity includes Adamson Philip B. sold 1.26K, Hykes Kevin sold 7.76K, VERRASTRO PAUL sold 1.28K, OASHEIM JARED sold 1.74K, and John Robert Allen sold 3.96K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CVRX?: Yes. Rallies tracks CVRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CVRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CVRX. It does not provide personalized investment advice.